Webinar: Role Changes and Reversals
Caregivers often feel like they are caring for a child rather than their spouse or parent. This dialogue will uncover the role changes that people experience as they shift from care partners to caregivers. This Dementia Dialogues webinar explores how to manage the feelings that accompany the changes.
- Wednesday, October 18th, 3-4 PM Eastern (12-1 PM Pacific/ Arizona, 1-2 PM Mountain, 2-3 PM Central)
- Can’t make it to the live webinar? Don’t worry! Just register as if you will attend and we will send you a recording that you can view at your convenience
- Sign up here
For those who prefer to join by phone, we also offer an audio version of the Dementia Dialogues webinars. Email firstname.lastname@example.org for details.
Thank you again for being a part of the Alzheimer’s Prevention Registry, and thank you for all you do to care for someone with Alzheimer’s.
On Wednesday, US drugmaker Eli Lilly announced that the Phase 3 clinical trial of its drug solanezumab did not progress as planned.
“Patients treated with solanezumab did not experience a statistically significant slowing in cognitive decline compared to patients treated with placebo,” the company said in a statement.
In a statement, Lilly’s chairman, president and CEO John C. Lechleiter said the company was “disappointed for the millions of people waiting for a potential disease-modifying treatment for Alzheimer’s disease.”
Read the full article on CNN.
I came across this call for participants through the Stanford University Center on Longevity, and thought I would spread the word. They are currently recruiting participants, looking for healthy adults aged 65-83 with no history of cognitive impairment or mental illness. The goal is to investigate the genetic risk of developing dementia (through blood tests) and to investigate the safety and effectiveness of a medication (currently used to control diabetes) in preventing Alzheimer’s Disease.
I came across a short article on the US Against Alzheimer’s website, where they pose the question:
Can WHO Lead the Global Alzheimer’s Movement?
And I was relieved they asked it! I had also been thinking about this over the past week but had been hesitant to post about it. I guess I didn’t want to seem jaded since my internship with the WHO on the Global Network of Age-Friendly Cities was a bit on the disappointing side. But, I am glad to see I am not the only one who is skeptical about the WHO leading a global Alzheimer’s movement. Wait…
…I am going to call it a dementia movement. Alzheimer’s disease is the most common type of dementia. But, around 50% of people who meet a dementia diagnosis criteria don’t ever get a diagnosis, so we can really only say that Alzheimer’s is the most diagnosed type of dementia. There are many people who do not have Alzheimer’s disease and will benefit from this movement…
Back to the WHO. They are certainly a global leader in addressing health issues and health promotion, and that the work they do is challenging and important. But large scale, challenging, and important work occurs over a long-term of research, planning, and implementation. Shaping policy and all the work that goes behind that takes a long time. This will be a great help – large scale, challenging, and important work that will affect MILLIONS of people. They can affect the movement in their own way, but I hesitate to call them THE leaders.
In addition to the long-term project cycles, and to the criticisms in the article below, I also wonder: Isn’t there already a global dementia movement?